

# ForPatients

*by Roche*

Relapsing Multiple Sclerosis (RMS) Primary Progressive Multiple Sclerosis (PPMS)

## **A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis**

**Trial Status**  
Recruiting

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT07483450 YN44938

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).

**Hoffmann-La Roche**  
Sponsor

**Phase 4**  
Phase

---

**NCT07483450 YN44938**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years & <= 55 Years

**Healthy Volunteers**  
No

---